Phase 1 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with Primary Progressive Multiple Sclerosis (a specific type of MS that worsens steadily from the start), confirmed using internationally recognised diagnostic guidelines
- People aged between 18 and 55 years old
- People whose MS-related disability falls within a specific moderate range, measured using a standard MS disability scale called the EDSS (scores between 3 and 6)
- People whose disability has been documented as getting worse over the 2 years before screening, in a way that is not related to relapses (sudden flare-ups)
- People whose spinal fluid (cerebrospinal fluid) test has shown a specific abnormal finding called oligoclonal bands, which is a marker sometimes seen in MS
- Women who could become pregnant must be using an effective method of contraception, as recommended by specific medical guidelines
- People who have signed a written consent form confirming they agree to take part voluntarily
- People who are enrolled in the French social security system (confirm with trial site if this applies outside France)
Who may not be able to join:
- People who have had a relapse or new MS lesions visible on MRI in the past year
- People who have taken MS disease-modifying medications in the past year
- People who have received high-dose steroid treatment in the 30 days before joining the trial
- People for whom a lumbar puncture (spinal tap) would not be safe — for example, those with raised pressure in the skull, an infection at the injection site, a very low platelet count (below 50 G/L), or who are taking blood-thinning or clot-dissolving medications
- People who have taken part in another treatment-based clinical trial in the last 6 months
- People who are legally protected or under guardianship, people who are not free to make their own decisions, people who are pregnant or breastfeeding, anyone under 18, or anyone unable to give informed consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Laure MICHEL, Pr, Rennes University Hospital
Phone: 0299284321
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients experiencing at least one adverse effect
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.